Parameter
| Biomarker | Anti-outer membrane porin C antibody (OmpC) | Full name | Anti-outer membrane porin C antibody | Molecular Type | Immunoglobulin (IgG) |
|---|---|---|---|---|---|
| Molecular Formula | Human anti-OmpC (IgG): C₆₃₂H₉８₄N₁₆₄O₁₉６S₈ | Molecular Weight | ~150 kDa | Core Functional Dimensions | Disease subtype identification and activity assessment |
| Disease | Inflammatory Bowel Disease (IBD) | Disease Subtypes | / | ||
| Organ | Intestine | Test Sample / Technology Platform | Serum (ELISA, immunoblotting) | ||
| Pathobiological Mechanisms | (1) 50-55% of CD patients (5-10% of UC patients) have antibodies against outer membrane porin C of E. coli, which are associated with colonic involvement and stricture formation in CD; (2) The intestinal mucosal inflammation score (CDEIS) of CD patients with positive OmpC was significantly higher than that of patients with negative OmpC, indicating increased intestinal bacterial translocation; Combined ASCA test can improve the diagnostic specificity of CD from 78% to 89% | ||||
| Clinical Availability Status | Clinical Research Applications | ||||
| Notes and Dynamics | 1. Positive OmpC was an independent risk factor for early recurrence (within 6 months) in CD patients (OR=2.5); (2) The latest study explored the correlation between the level of OmpC antibody and the response of CD patients to ustekinumab (anti-IL-12/23), and the preliminary results showed that the response rate of positive patients was increased by 22% | ||||